These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 3558728)

  • 1. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects.
    Clemmons DR; Snyder DK; Williams R; Underwood LE
    J Clin Endocrinol Metab; 1987 May; 64(5):878-83. PubMed ID: 3558728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition.
    Snyder DK; Clemmons DR; Underwood LE
    J Clin Endocrinol Metab; 1988 Jul; 67(1):54-61. PubMed ID: 3379136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary carbohydrate content determines responsiveness to growth hormone in energy-restricted humans.
    Snyder DK; Clemmons DR; Underwood LE
    J Clin Endocrinol Metab; 1989 Oct; 69(4):745-52. PubMed ID: 2778033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
    Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
    Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent lipolytic effect of exogenous growth hormone during caloric restriction.
    Snyder DK; Underwood LE; Clemmons DR
    Am J Med; 1995 Feb; 98(2):129-34. PubMed ID: 7847429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
    Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in body composition of human immunodeficiency virus-infected males receiving insulin-like growth factor I and growth hormone.
    Ellis KJ; Lee PD; Pivarnik JM; Bukar JG; Gesundheit N
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3033-8. PubMed ID: 8768870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anabolic effects of growth hormone in obese diet-restricted subjects are dose dependent.
    Snyder DK; Underwood LE; Clemmons DR
    Am J Clin Nutr; 1990 Sep; 52(3):431-7. PubMed ID: 2203249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of low-dose recombinant human growth hormone in the treatment of malnourished elderly medical patients.
    Chu LW; Lam KS; Tam SC; Hu WJ; Hui SL; Chiu A; Chiu KC; Ng P
    J Clin Endocrinol Metab; 2001 May; 86(5):1913-20. PubMed ID: 11344184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The obese growth hormone (GH)-deficient dwarf rat: body fat responses to patterned delivery of GH and insulin-like growth factor-I.
    Clark RG; Mortensen DL; Carlsson LM; Carlsson B; Carmignac D; Robinson IC
    Endocrinology; 1996 May; 137(5):1904-12. PubMed ID: 8612530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial.
    Sevette A; Smith RC; Aslani A; Kee AJ; Hansen R; Barratt SM; Baxter RC
    Clin Nutr; 2005 Dec; 24(6):943-55. PubMed ID: 16083996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting.
    Grinspoon S; Corcoran C; Lee K; Burrows B; Hubbard J; Katznelson L; Walsh M; Guccione A; Cannan J; Heller H; Basgoz N; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4051-8. PubMed ID: 8923860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of anabolism in malnourished cancer patients receiving growth hormone: a clinical research center study.
    Tayek JA; Brasel JA
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2082-7. PubMed ID: 7608259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of growth hormone (GH) and somatomedin C in idiopathic GH-deficient subjects by intermittent pulsatile administration of synthetic human pancreatic tumor GH-releasing factor.
    Borges JL; Blizzard RM; Evans WS; Furlanetto R; Rogol AD; Kaiser DL; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1984 Jul; 59(1):1-6. PubMed ID: 6427267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.